Ginkgo biloba (EGb 761).

Ginkgolide B is a platelet-activating factor antagonist, so EGb 761 dampens one arm of normal platelet aggregation. Nattokinase acts on fibrin, and stacking the two pushes normal clotting in the same direction.

EPA shifts eicosanoid production toward less aggregatory species while ginkgolides block the platelet-activating factor receptor. The two act on different steps of the same normal process and their effects add.

Garlic organosulfur compounds reduce platelet aggregation through a separate route from the ginkgolide block of platelet-activating factor. Combining them is a recognised additive pairing on normal clotting.

High tocopherol intakes dampen platelet aggregation and interfere with vitamin K dependent carboxylation. Alongside a platelet-activating factor antagonist the effects on normal clotting add rather than cancel.

Salicin-derived salicylate reduces thromboxane production in platelets while ginkgolides block the platelet-activating factor receptor. Two different steps of normal aggregation are dampened at once.

A 2026 review groups this extract with Rhodiola rosea and ashwagandha among botanicals examined for mood-related endpoints. The pairing appears in the literature as a review grouping rather than as a tested combination. Read it as a formulation convention with a review naming both, not as a combination trial.

The same 2026 review covers ashwagandha and this extract in one set of botanicals evaluated for mood-related endpoints. Adaptogen-plus-circulatory-botanical blends are common in commerce for that reason. The review names both; it does not report them tested together.

Bacopa and this extract sit together in most botanical nootropic blends and are covered in the same systematic reviews of herbal preparations tested on cognition in older adults. They act through different mechanisms, so the pairing is a stack rather than a chemical interaction. Combination-specific evidence is not what those reviews report.

Ginkgolide B antagonises the platelet-activating factor receptor and ginger constituents inhibit thromboxane-mediated aggregation, so the two push platelet function the same way through different receptors. A review of supplements studied for vascular health flags bleeding considerations for combinations of this kind. This is an additive effect to flag, not a benefit to sell.

Curcuminoids inhibit platelet aggregation in vitro and this extract antagonises platelet-activating factor signalling, so combining them stacks two antiplatelet mechanisms. A 2025 review of supplements studied for vascular health acknowledges the associated bleeding considerations. The pairing is worth flagging to anyone on anticoagulant or antiplatelet medication.

The standardised extract is defined partly by its flavone glycosides, which hydrolyse to quercetin, kaempferol and isorhamnetin. Adding free quercetin therefore adds more of a compound the extract already delivers in glycoside form. Anyone dosing both is stacking the same aglycone from two sources.

Grape seed proanthocyanidins and the flavone glycosides in this extract are both polyphenol antioxidants that donate hydrogen atoms to radicals. The two are routinely blended in circulatory-support formulas. Both also have mild antiplatelet activity, which is the part of the overlap worth naming.

Pine bark proanthocyanidins and the terpene lactones of this extract are combined in circulatory blends, and both have described effects on platelet aggregation. The antioxidant chemistry overlaps and the platelet direction is the same. Count them together rather than separately when assessing clotting-related interactions.

When a flavonoid quenches a radical it becomes a flavonoid radical itself, and ascorbate can reduce it back to the active form. That recycling loop is standard antioxidant biochemistry and applies to the flavone glycosides in this extract. It describes chemistry in solution and in tissue, not a measured clinical outcome.

Coenzyme Q10 works inside the mitochondrial membrane while the extract's flavonoids act mainly in the aqueous and membrane-surface compartments. Blends aimed at circulatory support commonly carry both for that complementary distribution. The rationale is mechanistic; combination data is not what supports it.

Phosphatidylserine is a membrane phospholipid used in cognitive blends and is frequently combined with this extract. The two act on unrelated targets, one on membrane composition and one on blood flow and platelet signalling. The pairing is convention with a mechanistic rationale rather than a tested combination.

Alpha-GPC supplies choline for acetylcholine synthesis while this extract is used for its effects on blood flow and platelet-activating factor signalling. Nootropic blends pair them for that division of labour. No combination trial supports the pairing; the rationale is mechanistic.

Huperzine A inhibits acetylcholinesterase and is often blended with this extract in cognitive formulas. The mechanisms do not overlap, so the pairing is additive by design rather than by chemistry. Anyone combining cholinergic agents should be aware they stack.

Long-chain omega-3 fatty acids shift eicosanoid production toward less aggregatory species, and this extract antagonises platelet-activating factor signalling. Two different antiplatelet routes stack when the two are taken together. A 2025 review of supplements studied for vascular health raises exactly this class of bleeding consideration.

Vitamin K1 supports the synthesis of clotting factors while this extract acts against platelet activation, so the two work on opposite sides of haemostasis by unrelated mechanisms. The pairing does not cancel out neatly, because one acts on coagulation factors and the other on platelets. It is worth naming for anyone whose clotting is being monitored.

Caffeine and this extract appear together in focus formulas, one acting on adenosine receptors and the other on circulation and platelet-activating factor signalling. The combination is a commercial convention with no shared target. Nothing about the pairing changes how either is handled.

A randomised trial of a multi-nutrient supplement in healthy adults included this extract among the constituents alongside B vitamins. That design tests the blend, not the extract on its own, so the pairing is documented as a formulation rather than as an isolated interaction. The distinction matters when reading such a trial.